Monitoring treatment response in breast cancer is of great importance and FDG PET has demonstrated its utility in this indication. FDG PET must be performed in patients with advanced disease treated ...
Reston, Va.—Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission ...
Pretreatment 18 F-FDG PET/CT scans from three study populations (N = 100, N = 39, N = 70) were used, comprising two single-institutional protocols and one publicly available data set. A clinician (V.J ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001). This is an ASCO Meeting Abstract from the 2023 ASCO ...
Staging locally advanced breast cancer patients with 18 F-labeled fluorodeoxyglucose (FDG) PET-CT detected more distant metastases -- and thus reduced the number of patients who received combined ...
Miami Beach, Fla. — The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years ...
Positron emission tomography (PET) provided objective evidence of response to treatment with tocilizumab (Actemra) in giant cell arteritis, according to a study by researchers from the National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results